Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 plus Sintilimab vs Placebo plus Sintilimab in Advanced Cervical Cancer
CTR20202017Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of IBI310 in Cervical Cancer (CC), sponsored by Innovent Biologics. Started Oct 2020; status: completed.
02
Drugs
IBI310
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20202017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202017.